Guillain-Barre Syndrome (GBS) Epidemiology Forecast 2025-2034

Guillain-Barre syndrome is a rare autoimmune condition that affects approximately 100,000 people worldwide each year, with nearly 1 in 78,000 people diagnosed with GBS annually. It is most commonly found in people between the ages of 30 and 50.

Guillain-Barre Syndrome (GBS) Epidemiology Forecast Report Coverage

The “Guillain-Barre Syndrome (GBS) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Guillain-Barre syndrome (GBS). It projects the future incidence and prevalence rates of Guillain-Barre syndrome (GBS) across various populations. The study covers age, gender, and type as major determinants of the Guillain-Barre syndrome (GBS)-affected population. The report highlights patterns in the prevalence of Guillain-Barre syndrome (GBS) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Guillain-Barre syndrome (GBS) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Guillain-Barre Syndrome (GBS) Disease Overview

In Guillain-Barre syndrome (GBS), the peripheral nerves are attacked by the immune system, leading to symptoms like muscle weakness, numbness, and tingling. The symptoms appear suddenly and start in the feet and legs and then spread up to the arms and face. Studies show that Guillain-Barre syndrome can cause life-threatening complications if they affect the autonomic nerves. It is reported that certain infections and immune system-linked factors can trigger the Guillain-Barre syndrome.

Guillain-Barre Syndrome (GBS): Treatment Overview

Treatment for Guillain-Barre syndrome (GBS) is focused on reducing the severity of the disease and shorten the recovery time. The primary treatment includes either of two options: plasma exchange (plasmapheresis) or intravenous immunoglobulin therapy (IVIG). In plasmapheresis, plasma exchange filters the antibodies from the plasma that are attacking the nerves. On the other hand, intravenous injections of immunoglobulins can help in lessening the attack of the immune system on nerves.

Epidemiology

The Guillain-Barre syndrome (GBS) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Guillain-Barre syndrome (GBS) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Guillain-Barre syndrome (GBS) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Guillain-Barre syndrome affects approximately 100,000 people worldwide each year and is most commonly found among individuals between the ages of 30 and 50.
• According to a 2023 systematic review, the incidence of Guillain-Barre syndrome in cohort studies ranged from 0.30 to 6.08 cases per 100,000 people and from 0.42 to 6.58 cases per 100,000 person-years.
• Acute inflammatory demyelinating polyneuropathy (AIDP) is the most prevalent type of Guillain-Barre syndrome in the United States. Acute motor axonal neuropathy (AMAN), a rare type of GBS, is reported to account for 5% to 10% of cases.
• The National Organization for Rare Disorders states that 1 or 2 individuals per million are affected by Miller-Fisher syndrome (MFS), a form of GBS, in the United States.

Country-wise Guillain-Barre Syndrome (GBS) Epidemiology

The Guillain-Barre syndrome (GBS) epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Guillain-Barre syndrome (GBS) varies between countries owing to differences in genetic factors, frequency of infections (such as the flu or Zika virus), vaccination programs, and availability of medical care and diagnostic capabilities. According to data from the State Public Health Department, the number of people suspected of having Guillain-Barre syndrome in Maharashtra (India) increased to 163 on February 3, 2025, from 158 the day before. The number of suspected deaths stayed at five.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Guillain-Barre syndrome (GBS) based on several factors.
• Guillain-Barre syndrome (GBS) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of Guillain-Barre syndrome (GBS) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of Guillain-Barre syndrome (GBS) epidemiology in the 8 major markets?
• What will be the total number of patients with Guillain-Barre syndrome (GBS) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of Guillain-Barre syndrome (GBS) in the 8 major markets in the historical period?
• Which country will have the highest number of Guillain-Barre syndrome (GBS) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Guillain-Barre syndrome (GBS) during the forecast period of 2025-2034?
• What are the currently available treatments for Guillain-Barre syndrome (GBS)?
• What are the disease risks, signs, symptoms, and unmet needs of Guillain-Barre syndrome (GBS)?

This product will be delivered within 3-5 business days.